Optimisation of dialysate flow in on-line hemodiafiltration

Francisco Maduell a,*, Raquel Ojeda a, Marta Arias-Guillén a, Néstor Fontseré a, Manel Vera a, Elisabeth Massó a, Miquel Gómez a, Lida Rodas a, Giannina Bazán a, Mario Jiménez-Hernández a, Gastón Piñeiro a, Nayra Rico b

a Departamento de Nefrología y Trasplante Renal, Hospital Clínic de Barcelona, Barcelona, Spain
b Departamento de Bioquímica, Hospital Clínico de Barcelona, Barcelona, Spain

A R T I C L E   I N F O

Article history:
Received 24 November 2014
Accepted 22 March 2015
Available online 30 November 2015

Keywords:
Dialysate flow
On-line hemodiafiltration
Efficacy
Convective volume

A B S T R A C T

Introduction: Currently, on-line hemodiafiltration (OL-HDF) is the most effective technique. Several randomised studies and meta-analyses have shown a reduced mortality and a direct association with convective volume has been reported. At present, it has not been established if an increased dialysate flow (Qd) shows in improved results in terms of convective and depurative efficiency. We aim at assessing the effects of Qd variations on convective volume and its depurative capacity in patients on OL-HDF.

Material and methods: A total of 59 patients (45 men and 14 women) from a OL-HDF programme in which a monitor 5008 Cordiak with auto-substitution was used, were enrolled. Patients were assessed in 5 sessions with post-dilutional OL-HDF, using helixone-based dialyzers, with only Qd being changed (300, 400, 500, 600 and 700 mL/min). Serum levels of urea (60 Da), creatinine (113 Da), β2-microglobulin (11,800 Da), myoglobin (17,200 Da) and α1-microglobulin (33,000 Da) were measured at the beginning and at the end of each session, in order to estimate the percent reduction of such solutes.

Results: An increased dialysate volume per session was observed, from 117.9 ± 6.4 L with Qd 300 mL/min to 223.4 ± 12 L with Qd 700 mL/min. No changes were found in replacement volume or convective volume. Regarding diffusion, Qd increase was associated to a significantly increased dialysis dose, with an increased Kt from 68 ± 6.9L with Qd 300 mL/min to 75.5 ± 8.1 L with Qd 700 mL/min (P < 0.001), and a gradually increased percent reduction in urea associated to increased Qd with significantly lower levels being found with Qd 300 mL/min. No changes were found in other measured substances.

Conclusion: Qd variations in OL-HDF do not change convective volume. A higher Qd was associated to a slightly increased urea clearance with no change being observed for medium and large molecules. Qd optimisation to the minimal level assuring an adequate dialysis dose and allowing water and dialysate use to be rationalised should be recommended.

© 2015 The Authors. Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Optimización del flujo del líquido de diálisis en la hemodiafiltración on-line

Resumen

Introducción: La hemodiafiltración on-line (HDF-OL) es actualmente la técnica más efectiva. Varios estudios aleatorizados y metaanálisis han observado una reducción de la mortalidad, con una asociación en relación directa con el volumen convectivo. En el momento presente no está bien establecido si el aumento del flujo del líquido de diálisis (Qd) puede suponer mejores resultados en términos de eficacia convectiva y depurativa. El objetivo del estudio fue valorar, en pacientes en tratamiento con HDF-OL, el efecto de la variación del Qd sobre el volumen convectivo y su capacidad depurativa.

Material y métodos: Se incluyeron 59 pacientes, 45 varones y 14 mujeres que se encontraban en programa de HDF-OL con monitor 5008 Cordix con autosustitución. Cada paciente fue analizado en 5 sesiones con HDF-OL, con dializadores de helixona, en las que solo se varió el Qd (300, 400, 500, 600 y 700 ml/min). En cada sesión se determinaron concentraciones de urea (60 Da), creatinina (113 Da), β₂-microglobulina (11.800 Da), mioglobina (17.200 Da) y α₁-microglobulina (33.000 Da) en suero al inicio y al final de cada sesión, para calcular el porcentaje de reducción de estos solutos.

Resultados: Se objetivó un aumento de litros de Qd por sesión, desde 117,9 ± 6,4 L con Qd de 300 ml/min hasta 232,4 ± 12 L con Qd 700 ml/min. No se determinaron cambios en el volumen de sustitución ni en el volumen convectivo. En términos de difusión, el incremento del Qd mostró un aumento significativo de la dosis de diálisis, con un aumento de Kt de 68 ± 6,9 L con Qd 300 ml/min hasta 75,5 ± 7,3 L con Qd 700 ml/min (p < 0,001), y un aumento progresivo del porcentaje de reducción de urea con el incremento del Qd, que era significativamente inferior con Qd 300 ml/min. No se objetivaron cambios en el resto de moléculas estudiadas.

Conclusión: La variación del Qd en HDF-OL no modifica el volumen convectivo. Un mayor Qd mostró un discreto incremento de la depuración de la urea, sin variaciones en las medianas ni en las grandes moléculas. Es recomendable optimizar el Qd al mínimo posible que garantice una adecuada dosis de diálisis y permita racionalizar el consumo de agua y concentrado de diálisis.

© 2015 The Authors. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

National¹ and international² clinical practice guidelines recommend to provide at least a minimum dose of haemodialysis as determined by a Kt/V of 1.3 and a urea reduction ratio of 70%. Diffusive clearance is related to blood flow (Qb), dialysate flow (Qd), and the mass transfer-area coefficient (KoA). In one in vitro study, Léypoldt et al.³ showed that an increase in Qd from 500 ml/min to 800 ml/min conferred a 14% increase in urea KoA, due to improved distribution of dialysate and reduced mass transfer resistance across the membrane. These results were subsequently demonstrated in clinical practice, with a 5.7%⁴ increase in KoA and an 8.5% increase in K and Kt/V when Qd was changed from 500 ml/min to 750 ml/min.⁵ Through modifications in the manufacturing of dialyzers, the pharmaceutical industry has improved dialysate distribution in capillaries.⁶⁻⁸ It has been observed that an increase in Qd to beyond 600 ml/min does not correlate with better dialysis outcomes, as determined by Kt/V⁹ or clearance of molecules such as phosphorus and β₂-microglobulin.¹⁰

Haemodiafiltration is a dialysis technique that combines diffusion and convection, both processes having similar clearance capacities. Post-dilution on-line HDF (OL-HDF) has been demonstrated to improve intradialysis tolerance¹¹, increase survival¹² and more recently, several meta-analyses have confirmed reduced overall and cardiovascular mortality.¹²⁻¹⁵ Secondary analyses of the studies using death as a primary endpoint¹¹,¹⁴,¹⁵ observed an association between convective volume and survival. Therefore, a minimum convective volume of 23L per session was recommended until more conclusive scientific evidence became available.¹⁶,¹⁷

Initially, OL-HDF was performed with a Qd of 800 ml/min, because some of the dialysate was used as substitution solution.¹⁸,¹⁹ Later, newer monitors were able to differentiate dialysate destined for diffusion (usually 500 ml/min) from that destined for substitution (60–150 ml/min).²⁰ Now, with the aim of optimising the dialysate to the requirements of the dialyser, the 5008 monitors have a Qd autoswap system with an adjustable Qd/Qb ratio. The initial default setting recommended by the monitor for this factor was 1.2.²¹ This recommendation has subsequently been changed to a factor of 1.0 if Qb is equal to or greater than 400 ml/min, or 1.2 if Qb is less than 400 ml/min.

To assess and optimise the choice of dialysate, the aim of this study was to evaluate the effects of changes in Qd on the
convective volume and clearance capacity in patients on OL-HDF treatment.

Patients and methods

This was a single-centre study in stable haemodialysis patients. Fifty-nine patients were included, 45 men and 14 women, with a mean age of 67.0 ± 13 years (range 26–89 years), who were on a haemodialysis programme for a mean of 39.4 ± 42 months. The aetiology of chronic renal failure was chronic glomerulonephritis in 8 cases (13.6%), diabetic nephropathy in 14 cases (23.7%), polycystic disease in 6 cases (10.2%), vascular nephropathy in 13 cases (22%), urological causes in 6 cases (10.2%), systemic disease in 1 (1.7%), tubulo-interstitial nephritis in 2 (3.4%), and unknown aetiology in 9 (15.3%). All patients were dialysed via an arteriovenous fistula, except one patient who had a tunnelled central line.

Each patient received 5 different dialysis sessions, always mid-week, in which only Qd was changed, to either 300, 400, 500, 600, or 700 mL/min. Other dialytic parameters were kept constant in all sessions studied: dialysis time, 293.4 ± 15 min (240–300 min); Qb, 424 ± 4 mL/min (350–450 mL/min). The dialyser was not changed (80% FX80Cordiax, 20% FX80Cordiax), 5008 Cordiax monitor, post-dilution OL-HDF with auto-substitution system was used. The order of sessions was randomised.

The dialysis parameters collected at each session were: programmed time, actual duration of sessions; dialyser; Qb; initial and final weight; Kt, automatically measured by ionic dialysance; recirculation rate, measured by the temperature module; arterial pressure; venous pressure; transmembrane pressure; initial and final haemoglobin; volume of blood processed; and substitution volume.

Serum concentrations of urea (60 Da), creatinine (113 Da), β2-microglobulin (11,800 Da), myoglobin (17,200 Da) and α1-microglobulin (33,000 Da) were measured at the start and end of each session to calculate the percentage reduction of these solutes. The concentrations of urea and creatinine were measured using molecular absorption spectrometry on the ADVIA 2400 analyser (Chemistry System of Siemens Healthcare Diagnostics, Chicago, IL, USA). β2-Microglobulin (β2-m) and α1-microglobulin (α1-m) were measured by immunonephelometry with the BNII analyser (Siemens Healthcare Diagnostics). Myoglobin concentrations were measured by “sandwich” enzyme immunoassay with the Dimension EXL analyser (Siemens Healthcare Diagnostics). In all cases, dedicated reagents were used.

To correct for haemocencentration during dialysis, the percentage reductions pre- and post-treatment in plasma β2-m, myoglobin and α1-microglobulin were calculated using the Bergström and Wehle formula. 22

Statistical analysis was performed on the programme SPSS version 20.0 and results are expressed as mean ± standard deviation. For analysis of the statistical significance of quantitative parameters, the Student’s t-test was used for paired data, or ANOVA for repeated measures. A P-value < 0.05 was considered statistically significant.

Results

All dialysis sessions were carried out with no clinical incidents of note. The anticoagulation used was heparin sodium in 28.8%, low molecular weight heparin (tinzaparin) in 55.9%, and in the remaining 15.3%, no heparin was used.

The volume of dialysate passed per session increased from 117.9 ± 6.4 L with a Qd of 300 mL/min up to 232.4 ± 12 L with a Qd of 700 mL/min (Fig. 1). There were no differences in the other dialysis parameters, Qb, total blood processed by the monitor, needle gauge, recirculation, actual duration of sessions, initial weight, final weight, weight gain, or dialysis monitor measurements of initial and final haematocrit (Table 1).

The substitution volume was similar in all 5 Qd settings studied (Table 2), demonstrating that Qd affected neither substitution volume nor convective volume (Fig. 2). Table 2 shows that in all situations, there were no differences in arterial pressure, venous pressure, transmembrane pressure, Qd, ultrafiltration flow (QUF), or percentage of effective convective volume over total processed blood.

When Qd was increased, the dialysis dose and clearance of small molecules also increased. Qt increased significantly, from 68.0 ± 6.91 when Qd was 300 mL/min, up to 75.5 ± 7.3 L when Qd was 700 mL/min (Table 3), P < 0.001 in all situations. There was also a greater percentage reduction of urea with the increase in Qd, being significantly lower when Qd was 300 mL/min than in the other 4 study situations (Table 3).

When we evaluated the percentage reduction of creatinine, β2-m, myoglobin and α1-microglobulin, no significant differences were observed among the different study situations (Table 3).

Discussion

This study shows, in post-dilution OL-HDF, the comparison between different dialysis flow rates of 300 mL/min, 400 mL/min, 500 mL/min, 600 mL/min, and 700 mL/min, observing that changes in Qd did not lead to changes in...
Table 1 – Comparison of dialysis parameters for the 5 different Qd settings (n = 59).

<table>
<thead>
<tr>
<th>Qd (mL/min)</th>
<th>300</th>
<th>400</th>
<th>500</th>
<th>600</th>
<th>700</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Qb (mL/min)</td>
<td>423.72 ± 4</td>
<td>423.72 ± 4</td>
<td>423.72 ± 4</td>
<td>423.72 ± 4</td>
<td>423.72 ± 4</td>
<td>NS</td>
</tr>
<tr>
<td>Processed blood volume (L)</td>
<td>121.65 ± 10</td>
<td>122.04 ± 10</td>
<td>121.71 ± 10</td>
<td>121.49 ± 11</td>
<td>121.41 ± 11</td>
<td>NS</td>
</tr>
<tr>
<td>Needle gauge 15/16 (%)</td>
<td>8.6/91.4</td>
<td>8.6/91.4</td>
<td>8.6/91.4</td>
<td>8.6/91.4</td>
<td>8.6/91.4</td>
<td>NS</td>
</tr>
<tr>
<td>Recirculation (%)</td>
<td>14.17 ± 5.5</td>
<td>14.24 ± 4.2</td>
<td>14.36 ± 4.5</td>
<td>14.56 ± 4.7</td>
<td>15.1 ± 3.4</td>
<td>NS</td>
</tr>
<tr>
<td>Prescribed Td (min)</td>
<td>293.4 ± 15</td>
<td>293.4 ± 15</td>
<td>293.4 ± 15</td>
<td>293.4 ± 15</td>
<td>293.4 ± 15</td>
<td>NS</td>
</tr>
<tr>
<td>Delivered Td (min)</td>
<td>288.1 ± 15</td>
<td>288.1 ± 15</td>
<td>288.1 ± 15</td>
<td>287.6 ± 16</td>
<td>287.1 ± 16</td>
<td>NS</td>
</tr>
<tr>
<td>Initial weight (kg)</td>
<td>71.46 ± 17</td>
<td>71.30 ± 17</td>
<td>71.39 ± 17</td>
<td>71.14 ± 17</td>
<td>70.71 ± 17</td>
<td>NS</td>
</tr>
<tr>
<td>Final weight (kg)</td>
<td>69.39 ± 16</td>
<td>69.31 ± 16</td>
<td>69.35 ± 16</td>
<td>69.00 ± 16</td>
<td>68.53 ± 16</td>
<td>NS</td>
</tr>
<tr>
<td>Weight gain (kg)</td>
<td>2.07 ± 0.99</td>
<td>2.00 ± 1.00</td>
<td>2.05 ± 1.02</td>
<td>2.15 ± 0.95</td>
<td>2.10 ± 1.11</td>
<td>NS</td>
</tr>
<tr>
<td>Initial haematocrit (%)</td>
<td>30.9 ± 3.6</td>
<td>31.1 ± 4.5</td>
<td>31.3 ± 4.3</td>
<td>30.3 ± 3.9</td>
<td>30.9 ± 3.8</td>
<td>NS</td>
</tr>
<tr>
<td>Final haematocrit (%)</td>
<td>36.2 ± 5.4</td>
<td>35.9 ± 5.3</td>
<td>36.4 ± 5.6</td>
<td>35.4 ± 5.5</td>
<td>36.1 ± 5.2</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS, not significant; Qb, blood flow; Qd, dialysate flow; Td, dialysis time.

Table 2 – Comparison of substitution volume, total convective volume, infusion flow, ultrafiltration flow, and processed blood volume at different dialysate flow rates (n = 59).

<table>
<thead>
<tr>
<th>Qd</th>
<th>Arterial pressure (mmHg)</th>
<th>Venous pressure (mmHg)</th>
<th>TMP (mmHg)</th>
<th>Substitution volume (L/session)</th>
<th>Convective volume (L/session)</th>
<th>Qf (mL/min)</th>
<th>QUF (mL/min)</th>
<th>Percentage of convective volume over processed blood (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>300</td>
<td>–225 ± 23</td>
<td>217 ± 33</td>
<td>185.2 ± 19</td>
<td>31.39 ± 3.2</td>
<td>33.47 ± 3.0</td>
<td>109.2 ± 10</td>
<td>116.2 ± 10</td>
<td>27.6 ± 2.5</td>
</tr>
<tr>
<td>400</td>
<td>–222 ± 26</td>
<td>218 ± 26</td>
<td>188.9 ± 19</td>
<td>31.92 ± 3.2</td>
<td>33.90 ± 2.9</td>
<td>109.4 ± 11</td>
<td>117.5 ± 10</td>
<td>28.3 ± 3.9</td>
</tr>
<tr>
<td>500</td>
<td>–224 ± 28</td>
<td>216 ± 31</td>
<td>185.1 ± 23</td>
<td>31.61 ± 3.4</td>
<td>33.66 ± 3.2</td>
<td>109.8 ± 12</td>
<td>116.9 ± 11</td>
<td>27.7 ± 2.6</td>
</tr>
<tr>
<td>600</td>
<td>–225 ± 26</td>
<td>213 ± 25</td>
<td>185.5 ± 22</td>
<td>31.79 ± 3.6</td>
<td>33.94 ± 3.4</td>
<td>110.6 ± 12</td>
<td>118.0 ± 12</td>
<td>28.0 ± 2.8</td>
</tr>
<tr>
<td>700</td>
<td>–222 ± 23</td>
<td>216 ± 31</td>
<td>185.3 ± 18</td>
<td>31.28 ± 3.1</td>
<td>33.44 ± 3.1</td>
<td>109.2 ± 10</td>
<td>116.7 ± 10</td>
<td>27.6 ± 2.3</td>
</tr>
</tbody>
</table>

NS, not significant; P, probability; Qf, infusion flow; QUF, ultrafiltration flow; TMP, transmembrane pressure.

Convective volume. In addition, a slight increase was observed in urea clearance, with no changes in the other molecules studied: creatinine, β2-m, myoglobin, and α1-microglobulin. Therefore, it seems reasonable to optimise Qd to values that guarantee an adequate dialysis dose, considering that every 100 mL/min reduction in Qd equates to a 16% reduction in dialysate consumption: approximately 6 L per hour of dialysis.

On-line HDF is a safe technique that improves intradialytic tolerance and increases survival.12-15 The EuDial group redefined HDF as a blood purification therapy combining diffusive and convective solute transport using a high-flux membrane with a KUF (ultrafiltration coefficient) greater than 20 mL/h/mmHg/m² and a sieving coefficient for β2-m greater than 0.6, with an effective convective volume greater than 20% of the total blood volume processed,16 and no specification regarding Qd.

The main limiting factors in achieving high convective volumes are Qb, duration of session, and haemocoagulation. One previous study25 showed that increasing Qb was likely to be the best method to achieve a greater convective volume: for every 50 mL/min increase in Qb, the convective volume increased more than half a litre per hour. One subsequent study26 analysed the importance of dialysate surface area. The authors concluded that with the high flux dialysers currently available for OL-HDF modes, choice of dialysate surface area should be considered in the cost effectiveness; when KUF was greater than 45 mL/h/mmHg, the differences in both convective volume and clearance capacity were minimal. Increasing the duration of sessions will always be beneficial in achieving a greater convective volume and greater clearance capacity. The present study confirms the null influence that Qd has on convective volume.

Regarding clearance efficiency, only diffusion is affected by Qd. Clearance capacity for small molecules depends mainly on Qb, Qd, and the properties of the membrane (KoA). Clearance capacity for low molecular weight molecules can decrease with the increase in spaces not adequately reached by dialysate, because the yield worsens. Initially, increasing Qd was recommended to avoid this phenomenon, but in both in vitro and in vivo studies,3-5 only slight improvements in clearance were observed with an increase in Qd.

![Fig. 2 – Changes in convective volume according to Qd; n = 59; ANOVA for repeated measures.](image-url)
In recent years, the pharmaceutical industry, after studying classic dialysers with magnetic resonance imaging and computed tomography and observing spaces to which dialysate was not adequately distributed, introduced changes in the manufacture of dialysers.5–8 These structural modifications, aimed at changing the arrangement and packing of capillaries to make up the membrane, have optimised dialysate distribution across the membrane, thus improving yield. Following the introduction of these structural modifications, both in vitro9–10 and in vivo9,10 studies have demonstrated that an increase in Qd beyond 600 mL/min does not lead to a better clearance capacity in terms of Kt/V,9 KoA, phosphorus, or β2-microglobulin.10 Therefore, the diffusive efficiency conferred by Qd has decreased with the modifications in the dialysing manufacturer process, and it cannot be claimed that an increase in Qd leads to improved clearance. Nonetheless, the prescribing doctor must always individualise the dialysis parameters, including Qd, to achieve a minimum dose of Kt.

One limitation of this study is that it involved only one type of dialysers, with a helixone membrane. Therefore, further studies with different membranes and dialysers characteristics are needed to assess whether these results can be extrapolated or whether Qd should be individualised to each dialysers.

Using previously published data, and after analysing the results of this study, it seems reasonable to dialyse with a Qd of 400 mL/min or with a Qd/Qb autoflow of 1.0 when Qb is equal to or greater than 400 mL/min. This Qd is sufficient to achieve an adequate clearance capacity, optimising the dialysate used in each session.

**Conclusion**

Dialysate flow in OL-HDF does not affect convective volume. A higher Qd results in a slight increase in clearance capacity for urea (diffusion dependent), with no changes for medium and large molecules (convection dependent). It is recommended that Qd to be optimised to the minimum possible that guarantees an adequate dialysis dose (Kt or Kt/V) and allows rationalisation of water and dialysate concentrate consumption. Further studies are needed with different dialysers, to assess if these results can be extrapolated to all dialysers or if it is necessary to individualise Qd to each dialysers.

### Table 3 – Evaluation of the clearance efficiency at the difference dialysate flow rates (n = 59).

<table>
<thead>
<tr>
<th>Qd</th>
<th>300</th>
<th>400</th>
<th>500</th>
<th>600</th>
<th>700</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kt (L)</td>
<td>68.0 ± 6.9</td>
<td>71.3 ± 6.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>73.2 ± 6.6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>75.1 ± 7.3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>75.5 ± 7.3&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>% reduction urea</td>
<td>82.5 ± 4.9</td>
<td>83.6 ± 5.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>84.0 ± 4.8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>84.5 ± 5.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>84.1 ± 4.8&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>% reduction Cr</td>
<td>76.5 ± 4.9</td>
<td>77.0 ± 5.1</td>
<td>77.6 ± 5.5</td>
<td>77.4 ± 5.3</td>
<td>77.2 ± 5.2</td>
</tr>
<tr>
<td>% reduction β2-m</td>
<td>83.5 ± 4.3</td>
<td>83.8 ± 4.5</td>
<td>83.6 ± 4.3</td>
<td>83.9 ± 4.7</td>
<td>83.2 ± 4.1</td>
</tr>
<tr>
<td>% reduction myoglobin</td>
<td>72.1 ± 7.9</td>
<td>71.4 ± 7.3</td>
<td>71.8 ± 8.0</td>
<td>72.1 ± 8.3</td>
<td>70.2 ± 7.3</td>
</tr>
<tr>
<td>% reduction α1-microglobulin</td>
<td>20.9 ± 9.1</td>
<td>21.5 ± 7.8</td>
<td>19.6 ± 9.2</td>
<td>22.8 ± 9.3</td>
<td>20.7 ± 8.3</td>
</tr>
</tbody>
</table>

* P < 0.001 compared with 300.
<sup>a</sup> P < 0.001 compared with 400.
<sup>b</sup> P = 0.003 compared with 500.
<sup>c</sup> P < 0.001 compared with 500.
<sup>d</sup> P = 0.018 compared with 300.
<sup>e</sup> P = 0.004 compared with 300.

### Conflicts of interest

FM has received fees from Amgen, Baxter, Bellco, and Fresenius. The other authors declare no conflicts of interest.

### References